Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab versus placebo for chronic inducible urticaria
NL-OMON50883Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ligelizumab in chronic inducible urticaria (CIndU), sponsored by Novartis. Planned start Sep 2021; status: withdrawn.
02
Drugs
ligelizumab
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NL-OMON50883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50883.